- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 2 - How Advocacy and Policy Intertwine
In the past and, perhaps to some extent, today, the specialized care and medications required for the appropriate management of patients with rare diseases, such as hemophilia and SLE, was neither readily accessible nor affordable. A collaborative effort for advocacy by patients and physicians has gradually pushed the evolution of legislation and regulations to improve access to optimal management. Two such legislation are the Orphan Drug Act of 1983 and the Rare Diseases Act of 2002, which provided the incentives and means necessary to drive the pharmaceutical research and development to grow a flourishing drug market and pipeline for rare diseases. As a result, managed care policies continue to evolve in many ways, implementing mechanisms and policies to balance treatment access and costs with appropriate medication use and patient outcomes. Patient and physician advocacy for rare diseases prompted a wave of change, but the momentum will need to be maintained.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
